Literature DB >> 9187911

Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact.

G Hofmockel1, S Riess, I D Bassukas, J Dämmrich.   

Abstract

OBJECTIVE: Expression and prognostic impact of some exponents of the epidermal growth factor (EGF) family in renal cell carcinoma (RCC) were examined.
MATERIALS AND METHODS: EGF, transforming growth factor-alpha (TGF-alpha), EGF receptor (EGF-R), and c-erb B-2 were determined immunohistochemically in formalin-fixed paraffin-embedded tumor samples of 30 patients with locally confined RCCs. The prognostic significance of these growth factors and their receptors as well as of tumor stage and malignancy grade was examined with respect to survival and tumor recurrence by following up the fate of the patients after nephrectomy (mean follow-up time 5.2 years).
RESULTS: The members of the EGF family and their receptors studied were expressed to a variable degree in all RCCs investigated. However, using log-rank tests in Kaplan-Meier plots only tumor stage (p < 0.0007) and malignancy grade (p < 0.007) but none of the growth factors or receptors studied (p > 0.05, respectively) exhibited prognostic significance with respect to both survival and disease-free period. On the contrary, there was a significant correlation between EGF and TGF-alpha (p < 0.001), EGF and EGF-R (p = 0.028), EGF-R and c-erb B-2 (p = 0.0009), and-inversely related-between TGF-alpha and tumor stage (p = 0.047) and between EGF-R and malignancy grade (p = 0.03). The coexpression of the factors studied also showed no prognostic relevance.
CONCLUSION: The expression of these members of the EGF family seems not to bear evaluable prognostic information for clinical use in the case of RCC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187911     DOI: 10.1159/000474510

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  18 in total

1.  New treatments for kidney cancer.

Authors:  Jonathan Waxman; Laura Kenny; Sarah Ngan
Journal:  BMJ       Date:  2008-03-29

Review 2.  Targeted anti-cancer therapies for renal cancer.

Authors:  Robert J Amato; Jaroslaw Jac
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Targeted therapy in renal cancer.

Authors:  Tanya B Dorff; Amir Goldkorn; David I Quinn
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

4.  Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors.

Authors:  Toshio Kuwai; Toru Nakamura; Sun-Jin Kim; Takamitsu Sasaki; Yasuhiko Kitadai; Robert R Langley; Dominic Fan; Stanley R Hamilton; Isaiah J Fidler
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

5.  Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

Authors:  C Langner; M Ratschek; P Rehak; L Schips; R Zigeuner
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

Review 6.  [Application of tissue microarrays for the diagnosis, prognosis and therapeutic decision making in renal cell carcinoma].

Authors:  A S Merseburger; J Hennenlotter; D Schilling; K D Sievert; R Küfer; M A Kuczyk
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

7.  Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma.

Authors:  Marcus Thomasson; Håkan Hedman; Börje Ljungberg; Roger Henriksson
Journal:  BMC Res Notes       Date:  2012-05-03

8.  Multiple biomarker tissue arrays: A computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway.

Authors:  V Medina Villaamil; G Aparicio Gallego; M Valladares-Ayerbes; I Santamarina Caínzos; L Miguel Antón Aparicio
Journal:  J Mol Signal       Date:  2012-09-01

9.  Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma.

Authors:  Yeong-Shiau Pu; Chao-Yuan Huang; Yi-Zih Kuo; Wang-Yi Kang; Guang-Yaw Liu; A-Mei Huang; Hong-Jeng Yu; Ming-Kuen Lai; Shu-Pin Huang; Wen-Jeng Wu; Shean-Jaw Chiou; Tzyh-Chyuan Hour
Journal:  J Biomed Sci       Date:  2009-09-12       Impact factor: 8.410

Review 10.  Crossing paths in Human Renal Cell Carcinoma (hRCC).

Authors:  Guadalupe Aparicio Gallego; Vanessa Medina Villaamil; Enrique Grande; Isabel Santamarina Caínzos; Luís M Antón Aparicio
Journal:  Int J Mol Sci       Date:  2012-10-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.